1. 008 BP: SYSTEMS RESILIENCE: IMPROVING PUBLIC HEALTH THROUGH COLLABORATION AND COMMUNITY BASED PARTICIPATORY RESEARCH. (3rd March 2017) Authors: Porroche-Escudero, A; Popay, J; Barr, B; Mosedale, S; Ring, A; Sadler, G; Simpson, G; Wheeler, P Journal: BMJ open Issue: Volume 7:Supplement 2(2017) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 115PPathological complete response rates following neoadjuvant systemic therapy in 300 patients with early or locally advanced HER2 positive breast cancer: The Royal Marsden experience. (13th May 2019) Authors: Chaabouni, N; Battisti, N M L; True, V; Chopra, N R; Shepherd, S T C; Lee, K; Joshi, R; Kabir, M; Allen, M; Ring, A Journal: Annals of oncology Issue: Volume 30(2019)Supplement 3 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 1339 IMPROVING INPATIENT MANAGEMENT OF DELIRIUM IN A DISTRICT GENERAL HOSPITAL. (16th January 2023) Authors: Juwarkar, A; Ahmed, S; Franks, S; Ring, A Journal: Age and ageing Issue: Volume 52(2023)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. 1572PIs age a barrier to chemotherapy? Rates of treatment in older patients with breast, colon or lung cancer in England in 2014: A national registry study. (23rd October 2018) Authors: Battisti, N M L; Wallington, M; Ring, A; Payne, S; Birch, R; Bomb, M; Seligmann, J; Kalsi, T; Hounsome, L; Dodwell, D; Underhill, S; Mensah, L; Morris, E; Selby, P J; Mansi, J Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. 182PEfficacy and tolerability of neratinib in advanced HER-2 positive breast cancer: A single institution experience. (13th May 2019) Authors: Shepherd, S T C; Lee, K; Mohammed, K; Patel, K; Allen, M; Johnston, S R D; Parton, M; Ring, A; Turner, N; Okines, A F C Journal: Annals of oncology Issue: Volume 30(2019)Supplement 3 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. 19 The randomised complete vs. lesion only primary PCI trial – cardiovascular MRI substudy (CVLPRIT-CMR). (26th April 2015) Authors: Khan, JN; Greenwood, JP; Nazir, SA; Dalby, M; Curzen, N; Hetherington, S; Kelly, DJ; Blackman, D; Ring, A; Peebles, C; Wong, J; Flather, M; Swanton, H; Gershlick, AH; McCann, GP Journal: Heart Issue: Volume 101(2015)Supplement 2 Page Start: A10 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. 293PD_PRRibociclib (RIBO) + letrozole (LET) in male patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor-2–negative (HER2–) advanced breast cancer (ABC) and no prior endocrine therapy (ET) for ABC: Preliminary subgroup results from the phase IIIb CompLEEment-1 trial. (23rd October 2018) Authors: Zamagni, C; Campone, M; Kudryavcev, I; Brown-Glaberman, U; Cottu, P H; Ring, A; Lu, J; Martín, M; De Laurentiis, M; Zhou, K; Wu, J; Menon, L; Azim, H A Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. 328PRibociclib (RIBO) + letrozole (LET) in premenopausal patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor-2–negative (HER2–) advanced breast cancer (ABC) with no prior endocrine therapy (ET) for ABC: Preliminary subgroup results from the phase IIIb CompLEEment-1 trial. (23rd October 2018) Authors: Abdel-Razeq, H; Cottu, P H; Ring, A; De Laurentiis, M; Lu, J; Azim, H A; Zamagni, C; Zhou, K; Wu, J; Menon, L; Martín, M Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. 333PRibociclib (RIBO) + letrozole (LET) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor-2–negative (HER2–) advanced breast cancer (ABC) who received prior chemotherapy (CT) for advanced disease: Preliminary subgroup results from the phase IIIb CompLEEment-1 trial. (23rd October 2018) Authors: Cardoso, F; Papazisis, K; De Laurentiis, M; Ring, A; Lu, J; Martín, M; Azim, H A; Zamagni, C; Zhou, K; Wu, J; Zarate, J P; Cottu, P H Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. A young woman with chest pain. Issue 6 (1st December 2000) Authors: Missouris, C G; Ring, A; Ward, D Journal: Heart Issue: Volume 84:Issue 6(2000) Page Start: e12 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗